Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
FARESTON vs OSPEMIFENE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Selective estrogen receptor modulator (SERM) that competitively binds to estrogen receptors, exerting antiestrogenic effects in breast tissue.
Ospemifene is a selective estrogen receptor modulator (SERM) that acts as an agonist on estrogen receptors in vaginal tissues, leading to proliferation and maturation of vaginal epithelium, while exhibiting antagonist activity on breast and endometrial tissues.
FDA-approved for the treatment of metastatic breast cancer in postmenopausal women with estrogen receptor-positive tumors,Off-label: treatment of advanced breast cancer in premenopausal women in combination with ovarian suppression
Treatment of moderate to severe dyspareunia (painful intercourse) due to vulvar and vaginal atrophy associated with menopause
60 mg orally once daily.
60 mg orally once daily.
The terminal elimination half-life of toremifene is approximately 5 days (range 2-10 days). The half-life of its main metabolite, N-desmethyltoremifene, is about 11 days. This long half-life supports once-daily dosing.
Terminal elimination half-life is approximately 26 hours (range 20–30 hours), supporting once-daily dosing.
Primarily hepatic via CYP3A4 and CYP1A2; undergoes glucuronidation; active metabolite N-desmethyltoremifene
Primarily metabolized via CYP3A4 and CYP2C9, with minor contributions from CYP2C19, CYP2C8, and CYP2B6. Undergoes glucuronidation and sulfation.
FARESTON (toremifene) is extensively metabolized in the liver. Excretion is primarily fecal (approximately 70%) with renal excretion accounting for less than 10% of the dose as unchanged drug and metabolites.
Primarily hepatic metabolism with biliary excretion; < 30% renal elimination as metabolites. Fecal excretion accounts for approximately 70% of total clearance.
Toremifene is >99% bound to plasma proteins, primarily albumin.
> 99% bound to serum proteins, primarily albumin.
The apparent volume of distribution (Vd) is approximately 580 L (about 8 L/kg for a 70 kg individual), indicating extensive tissue distribution.
Approximately 4.2 L/kg, indicating extensive tissue distribution.
Oral bioavailability of toremifene is not precisely determined but is estimated to be nearly 100% based on absorption and first-pass metabolism studies.
Oral bioavailability is approximately 20–30% due to first-pass metabolism.
No dose adjustment required for GFR ≥30 m L/min; insufficient data for GFR <30 m L/min.
No dose adjustment required for mild to moderate renal impairment (Cr Cl ≥15 m L/min). Not studied in severe renal impairment (Cr Cl <15 m L/min) or dialysis.
Contraindicated in Child-Pugh class C; use with caution in class A or B without specific dose reduction guidelines.
Contraindicated in Child-Pugh Class C (severe hepatic impairment). No dose adjustment for Child-Pugh Class A or B; use with caution.
Safety and efficacy not established; no recommended dose.
Not indicated for pediatric use; safety and efficacy not established.
No specific dose adjustment; monitor renal function and electrolyte balance.
No specific dose adjustment required; pharmacokinetics similar to younger adults. Monitor for vulvovaginal atrophy and thromboembolic risks.
None
There is an increased risk of endometrial cancer in women with an intact uterus. Use only when necessary and consider periodic endometrial evaluation.
QT interval prolongation,Hypercalcemia in patients with bone metastases,Endometrial hyperplasia/cancer risk,Thromboembolic events,Ocular toxicity (dose-dependent retinopathy),Tumor flare
Endometrial cancer risk,Cardiovascular and cerebrovascular events (not evaluated in long-term studies),Venous thromboembolism (potential risk),Breast cancer (long-term safety not established),Use with caution in patients with hepatic impairment
Hypersensitivity to toremifene or any excipients,History of thromboembolic disease,Pre-existing endometrial hyperplasia,Patients with long QT syndrome or concurrent use of QT-prolonging drugs
Undiagnosed abnormal genital bleeding,Known or suspected estrogen-sensitive cancer (e.g., breast cancer),Active or history of venous thromboembolism (e.g., deep vein thrombosis, pulmonary embolism),Pregnancy or women who may become pregnant
Avoid grapefruit and grapefruit juice due to CYP3A4 inhibition, which can increase toremifene levels and risk of adverse effects. No other significant food interactions known. Take with or without food.
Take with food to minimize GI side effects. No specific food restrictions; however, avoid grapefruit juice as it may increase drug levels via CYP3A4 inhibition.
Pregnancy Category D. First trimester: Risk of fetal harm, including spontaneous abortion and congenital malformations (e.g., craniofacial, cardiac). Second and third trimesters: Potential for fetal hypothalamic-pituitary-gonadal axis disruption, ambiguous genitalia in female fetuses, and other adverse effects based on animal studies.
Ospemifene is contraindicated in pregnancy due to potential fetal harm. In animal studies, it caused fetal malformations (e.g., skeletal abnormalities) and embryo-fetal loss. There are no adequate human data; however, based on its estrogenic and antiestrogenic activity, it may interfere with fetal development. Use is not recommended at any trimester.
Not recommended during breastfeeding. Toremifene may be excreted in human milk; M/P ratio not established. Potential for serious adverse reactions in nursing infants, including hormonal disruption.
It is unknown whether ospemifene is excreted in human breast milk. No M/P ratio is available. Due to potential serious adverse effects in the nursing infant, breastfeeding is not recommended during treatment and for one week after the last dose.
No established dose adjustments; use contraindicated in pregnancy. Pharmacokinetic changes (increased volume of distribution, altered clearance) may require empirical dose reduction if used inadvertently, but no specific guidelines exist. Avoid use.
Ospemifene is contraindicated in pregnancy; therefore, no dosing adjustments are recommended. If pregnancy occurs, therapy should be discontinued. Due to lack of data and potential harm, no alternative dosing during pregnancy is advised.
FARESTON (toremifene) is a selective estrogen receptor modulator (SERM) used for metastatic breast cancer in postmenopausal women with estrogen receptor-positive tumors. Unlike tamoxifen, toremifene has a longer half-life (about 5 days) and may have a lower risk of thromboembolic events. Monitor liver function tests regularly due to potential hepatotoxicity. Prolongation of QT interval has been reported; avoid in patients with pre-existing QTc prolongation or with other QT-prolonging drugs. Use with caution in patients with endometrial hyperplasia or history of thromboembolic disease.
Ospemifene is a selective estrogen receptor modulator (SERM) indicated for moderate to severe dyspareunia due to vulvar and vaginal atrophy (VVA) in postmenopausal women. It has estrogenic effects on vaginal tissue but antiestrogenic effects on breast and endometrium. Monitor for thromboembolic events; contraindicated in history of VTE or PE. Not for use in women with breast cancer or estrogen-dependent neoplasia. May cause hot flashes and vaginal discharge.
Take this medication exactly as prescribed, usually once daily with or without food.,You may experience hot flashes, nausea, or sweating; these are common and usually manageable.,Report any unusual vaginal bleeding, discharge, or pelvic pain to your doctor immediately.,Watch for signs of blood clots such as leg pain/swelling, sudden chest pain, or shortness of breath.,Avoid grapefruit and grapefruit juice while on this medication as they may increase side effects.,Use non-hormonal contraception if you are still able to become pregnant; toremifene can harm a fetus.,Do not stop or change your dose without consulting your healthcare provider.
Take one 60 mg tablet daily with food to reduce gastrointestinal upset.,Notify your healthcare provider if you experience unusual vaginal bleeding, breast pain, or lumps.,Seek immediate medical attention for signs of blood clots: chest pain, shortness of breath, leg swelling or pain, sudden severe headache.,Do not use if you have a history of blood clots, breast cancer, or liver disease.,Ospemifene is for non-surgical women postmenopausal; it does not prevent pregnancy or sexually transmitted infections.,Avoid smoking and limit alcohol intake to reduce the risk of blood clots.
No interactions on record
"Ospemifene, a selective estrogen receptor modulator, inhibits the metabolism of thiotepa, an alkylating agent, by competitively inhibiting cytochrome P450 (CYP) 2B6 and potentially other CYP enzymes involved in thiotepa's biotransformation. This leads to increased systemic exposure to thiotepa, elevating the risk of dose-dependent toxicities such as severe myelosuppression (e.g., neutropenia, thrombocytopenia) and mucositis. Clinically, coadministration may require significant thiotepa dose reduction to avoid excessive bone marrow suppression."
"Ospemifene is primarily metabolized by CYP3A4, and thioridazine is a moderate inhibitor of CYP3A4. Coadministration reduces ospemifene clearance, leading to elevated ospemifene serum concentrations, which may increase the risk of dose-dependent adverse effects such as thromboembolic events, hot flashes, and vaginal discharge. This interaction is clinically significant as it may exacerbate the endocrine and cardiovascular side effects of ospemifene."
"Ospemifene, a selective estrogen receptor modulator (SERM), is primarily metabolized by the cytochrome P450 enzyme CYP3A4. Clarithromycin is a potent macrolide antibiotic and a strong inhibitor of CYP3A4. Coadministration of clarithromycin with ospemifene significantly reduces the metabolic clearance of clarithromycin, leading to increased plasma concentrations of clarithromycin. This elevation can potentiate clarithromycin's adverse effects, including QT interval prolongation, cardiac arrhythmias, hepatotoxicity, and gastrointestinal disturbances, particularly in patients with preexisting risk factors."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about FARESTON vs OSPEMIFENE, answered by our medical review team.
FARESTON is a Selective Estrogen Receptor Modulator that works by Selective estrogen receptor modulator (SERM) that competitively binds to estrogen receptors, exerting antiestrogenic effects in breast tissue.. OSPEMIFENE is a Selective Estrogen Receptor Modulator (SERM) that works by Ospemifene is a selective estrogen receptor modulator (SERM) that acts as an agonist on estrogen receptors in vaginal tissues, leading to proliferation and maturation of vaginal epithelium, while exhibiting antagonist activity on breast and endometrial tissues.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between FARESTON and OSPEMIFENE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of FARESTON is: 60 mg orally once daily.. The standard adult dose of OSPEMIFENE is: 60 mg orally once daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between FARESTON and OSPEMIFENE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. FARESTON is classified as Category C. Pregnancy Category D. First trimester: Risk of fetal harm, including spontaneous abortion and congenital malformations (e.g., craniofacial, cardiac). Second and third trimesters: P. OSPEMIFENE is classified as Category C. Ospemifene is contraindicated in pregnancy due to potential fetal harm. In animal studies, it caused fetal malformations (e.g., skeletal abnormalities) and embryo-fetal loss. There. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.